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Human epididymis protein 4 (HE4) is an important clinical biomarker used for the detec-
tion of epithelial ovarian cancer (EOC). While much is known about the predictive power 
of HE4 clinically, less has been reported regarding its molecular role in the progression 
of EOC. A deeper understanding of HE4’s mechanistic functions may help contribute to 
the development of novel targeted therapies. Thus far, it has been difficult to recommend 
HE4 as a therapeutic target owing to the fact that its role in the progression of EOC has 
not been extensively evaluated. This review summarizes what is collectively known about 
HE4 signaling and how it functions to promote tumorigenesis, chemoresistance, and 
metastasis in EOC, with the goal of providing valuable insights that will have the potential 
to aide in the development of new HE4-targeted therapies.
Keywords: human epididymis protein 4, epithelial ovarian cancer, tumorigenesis, chemoresistance, metastasis
iNTRODUCTiON
Approximately 22,280 new cases of epithelial ovarian cancer (EOC) are diagnosed each year, result-
ing in 14,240 deaths annually in the United States (1). The 5-year survival rate for stage III ovarian 
cancer is only 39% (1). These dire statistics are due to the fact that the disease is frequently detected 
at an advanced stage, which drastically impacts overall patient survival. Initially, many patients 
respond well to first-line therapy that includes cytoreduction surgery and platinum-based treatment. 
However, many patients experience a chemoresistant recurrence within the first 2 years following 
treatment (2). Therefore, there is an urgent need for tools to aid in the early diagnosis of ovarian 
cancer when the disease is fundamentally curable, as well as improved treatment options for later 
stage disease.
Human epididymis protein 4 (HE4) is a secretory protein that is member of the whey acidic 
protein domain family, bearing a conserved motif found in a number a protease inhibitors (3). HE4 
was initially suggested to be involved in the innate immune defense of multiple epithelia and has 
also been found to function in epithelial host defense (4). In ovarian tissue, HE4 is highly over-
expressed in EOC compared normal tissue (5, 6). Clinically, HE4 has been identified as a novel 
therapeutic biomarker for EOC and has also proven useful in detection of recurrent disease (7) 
Serum HE4 level predicts EOC with equal sensitivity to the established biomarker CA125 and is less 
likely to be elevated in benign disease (5). A multicenter study led by our institution established the 
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FDA-approved Risk of Ovarian Malignancy Algorithm (ROMA), 
which combines menopausal status and serum levels of both HE4 
and CA125 to detect and monitor EOC. ROMA demonstrates 
improved sensitivity and specificity over the Risk of Malignancy 
Index that uses CA125 alone as a serum based biomarker (6). 
Recently, it has been reported that HE4 can be detected in EOC 
patient urine, indicating the possibility that it may be utilized as 
a non-invasive biomarker (8).
While HE4 has been well studied in the clinical setting, less 
is known regarding its specific molecular and biological roles 
in EOC. Several studies have investigated its effect on gene 
expression in EOC cells, as well as on events associated with 
aggressive disease. This review will summarize HE4’s effect on 
cell proliferation and tumor growth; invasion, migration, and 
adhesion; chemoresistance; and steroid biosynthesis (Figure 1). 
Each section will detail associated pathways and factors that are 
reported to be involved in these HE4-mediated effects, with the 
goal of revealing common themes in signaling pathways affected 
by HE4 and exposing gaps in our knowledge of HE4 molecular 
and biological functions.
CeLL PROLiFeRATiON AND TUMOR 
GROwTH
Within the past 5 years, a handful of in vitro and in vivo studies 
have begun to examine HE4’s role in proliferation and tumor 
growth in EOC. A study by Wang et al. examined the role of HE4 
in cell proliferation and found that cells treated with recombinant 
HE4 formed a statistically greater number of colonies compared 
with control treated cells (9). Furthermore, cells stimulated with 
recombinant HE4 exhibited greater cell viability compared with 
respective controls. In another study by Zhu et  al. (10), prolif-
eration rate in two different HE4-overexpressing cell lines was 
significantly higher than in the control cells. Likewise, Zhu et al. 
(11) and Lee et al. (12) determined that when HE4 was ablated 
via shRNA, cell proliferation decreased accordingly. Kong et al. 
report conflicting results, stating that HE4 inhibits proliferation 
in ovarian cells (13); however, no other studies support these 
claims, necessitating further explanation to understand the 
implications of their results.
Several in vitro studies suggest that HE4 promotes proliferation 
through its involvement in cell cycle regulation (11). Silencing of 
HE4 causes G0/G1 cell cycle arrest and blocks the transition from 
the G1 to the S phase of the cell cycle. Conversely, when cells 
are stimulated with recombinant HE4, the number of cells in the 
G2/M phase is increased, while the number of cells in the G0/G1 
phase is reduced (9). These results indicate that HE4 may mediate 
the cell cycle by promoting the G0/G1 transition. In addition, 
in  vivo tumorigenicity studies using HE4 knockdown clones 
revealed a marked inhibition in the growth of ovarian tumors in 
nude mice (14), while injection of HE4-overexpressing cells led 
to more aggressive tumor growth and an overall higher tumor 
volume compared with controls (10, 15). Taken together, results 
from numerous in vitro and in vivo studies provide compelling 
evidence that HE4 plays a role in cell proliferation and the 
promotion of tumorigenesis. A full list of factors associated with 
HE4-mediated cell proliferation and tumor growth can be found 
in Table 1A and is outlined in greater detail below.
Associated Pathways and Factors—Cell 
Proliferation and Tumor Growth
Human epididymis protein 4 has been connected to several 
oncogenic signaling cascades that play key roles in ovarian cancer 
progression, including the PI3K/AKT pathway, HIF1α, and ERK/
mitogen-activated protein kinase (MAPK) signaling. Evidence of 
HE4’s effect on activation of each of these pathways is discussed 
below.
Protein Kinase B Signaling
AKT has been established as a strong promoter of tumorigen-
esis, and the PI3K/AKT pathway is one of the most commonly 
hyperactivated pathways in many types of human cancers (16). 
Its diverse signaling regulates proliferation, growth, survival, 
motility, angiogenesis, and glucose metabolism (17). HE4-
overexpressing OVCAR3 ovarian cancer cells were found to 
have a marked increase in activation of protein kinase B (AKT) 
compared with control cells, while HE4 knockdown in OVCAR3 
cells reduced AKT activation (12). Moreover, it was found that 
HE4-overexpressing SKOV3 clones had naturally higher gene 
levels of AKT3 compared with the null-vector control (18), bol-
stering the claim that HE4 affects the PI3K/AKT pathway.
Hypoxia-Inducible Factor-1 Alpha (HIF1α)
Adaptation of malignant cells to hypoxic conditions is a key step 
in the promotion of tumorigenesis and angiogenesis (19–21), 
a process that is regulated by the transcription factor HIF1α. 
Co-immunoprecipitation revealed an interaction between HIF1α 
and HE4 in HE4-overexpressing SKOV3 xenografts. There was 
also strong colocalization of HE4 and HIF1α in SKOV3 ovarian 
xenograft tissue. In addition, when SKOV3 cells were treated with 
HIF1α siRNA or 2-methoxyestradiol (a HIF1α inhibitor), there 
was a marked decrease in HE4 protein levels (15). It is important 
to note that 2-methoxyestradiol is not a specific HIF1α inhibitor as 
it primarily causes the depolymerization of microtubules, which 
in turn prevents HIF1α expression (22). Thus, the specificity of 
the effect of HIF1α inhibition on HE4 levels may require further 
investigation. Although the exact mechanism and significance 
of the HE4-HIF1α interaction is not understood, this evidence 
suggests that HE4 could play a role in regulating HIF1α functions 
in angiogenesis.
MAPK Signaling
The MAPK pathway is composed of a family of conserved 
kinases that mediate essential cellular processes such as migra-
tion, growth, proliferation, differentiation, and apoptosis (23). 
The extracellular signal-regulated kinase (ERK) pathway is the 
best characterized of all MAPK pathways and is deregulated 
in approximately one-third of all cancers. Several studies have 
shown activation of ERK in response to HE4 treatment or over-
expression, or suppression of ERK phosphorylation in response 
to HE4 knockdown (11, 12, 18). Using microarray analysis, Zhu 
et al. determined that seven genes involved in the MAPK path-
way (CHUK, GADD45A, IL1A, RPS6KA1, HSPA1B, DUSP1, 
FiGURe 1 | Graphical representation of clinical, in vivo and in vitro studies completed relating to HE4 and EOC, as well as associated pathways and mechanisms.
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TABLe 1 | Summary of factors associated with human epididymis protein 4 (HE4) in epithelial ovarian cancer (EOC).
Gene symbol Description Association
(A) Cell proliferation and tumor growth
AKT Protein kinase B •	 Upregulated in overexpressing OVCAR3 HE4 cell lines (10)
•	 Decreased in response to HE4 knockdown in OVCAR3 cells (10)
•	 Upregulated in HE4 SKOV3 clones compared with vector control (16)
HIF1α Hypoxia-inducible factor-1 alpha •	 Co-immunoprecipitation with HE4 SKOV3 xenograft tissue (13)
•	 Colocalization with HE4 in SKOV3 xenograft tissue (13)
•	 Treatment with 2-methoxyestradiol leads to marked decrease in HE4 (13)
ERK Extracellular signal-regulated kinase •	 Decrease in p-ERK when HE4 was silenced in SKOV3 cells (9)
•	 Corresponding decrease and increase in ERK when HE4 was  
downregulated and overexpressed in OVCAR3 cells (10)
•	 Increase in p-ERK in SKOV3 and OVCAR8 cells with recombinant HE4 treatment (16)
CHUK Conserved helix–loop–helix ubiquitous kinase •	 Upregulation when HE4 was induced in ES-2 cells (8)
GADD45A Growth arrest and DNA-damage-inducible  
protein GADD45 alpha
IL1A Interleukin-1 alpha
RPS6KA1 Ribosomal protein S6 kinase alpha 1
HSPA1B Heat shock 70 kDa protein 1B,
DUSP1 Dual specificity protein phosphatase 1
JUND Transcription factor JunD
EGF/EGFR Epidermal growth factor/epidermal growth  
factor receptor
•	 Co-immunoprecipitation with HE4 SKOV3 xenograft tissue (13)
•	 Colocalization with HE4 in SKOV3 xenograft tissue (13)
•	 HE4 overexpressed in OVCAR8 cells when stimulated with recombinant protein (13)
•	 HE4 increased when inhibited by IRESSA (13)
VEGF Vascular endothelial growth factor •	 HE4 overexpressed in OVCAR8 cells when stimulated with recombinant protein (13)
INS Insulin
(B) invasion, migration, and adhesion
MMP-9 Matrix metallopeptidase 9 •	 Downregulated when HE4 is silenced in ovarian cell lines (9)
MMP-2 Matrix metallopeptidase 9
CTSB Cathepsin B
IL1A Interleukin-1 alpha •	 Microarray results reveal correlation with HE4 levels (8, 71)
•	 One microarray reports an inverse correlation with HE4 (16)
ITGβ5 Integrin β5 •	 Differentially regulated by HE4 in ES-2 and CaOV3 cells (8)
•	 Correlation with HE4 in paraffin embedded ovarian human tissue (8)
SDC1 Syndecan 1 •	 Differentially regulated in response to HE4 (71)
COL1A1 Collagen type 1 alpha 1
DAG1 Dystroglycan 1
LAMB3 Laminin-β3 •	 Increased expression when stimulated with recombinant  
HE4 in OVCAR8 cells (57)LAMC2 Laminin-γ2
GREM1 Gremlin 1
TNC Tenascin C
SERPIND2 Serine peptidase inhibitor member 2
LAMA3 Laminin 332 •	 Increased in response to HE4 stimulation of LAMB3 and LAMC2 (57)
Lewis y antigen •	 Colocalized with HE4 in human ovarian tissue (98)
•	 Immunohistochemistry stained found correlative staining with HE4 (98)
•	 Overexpression promoted HE4-mediated invasion and metastasis in in vitro  
cell lines (99)
•	 Knockdown promoted a decrease in invasion and metastatic properties  
of HE4 (99)
SERPIN D1 Heparin cofactor II •	 Upregulated in HE4-overexpressing clones and downregulated in knockout  
in in vitro lines (71)
•	 Spearman analysis revealed positive correlation with HE4 in human  
EOC tissue immunohistochemistry staining (71)
•	 Poor patient prognosis when levels upregulated in combination with HE4 (71)
ANXA2 Annexin II •	 Mass spectrometry and co-immunoprecipitation identify as strong interacting  
partner of HE4 (58)
•	 Gene levels co-dependent with HE4 (58)
•	 Higher along with HE4 in EOC patients with lymph node metastasis than  
those without (58)
(Continued )
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Gene symbol Description Association
LAMB2 Laminin subunit beta-2 •	 Gene levels decreased in presence of HE4 knockdown cell line (58)
MKN2 MAP kinase-interacting serine/threonine-protein kinase 2
(C) Chemoresistance
EGR1 Early growth response protein 1 •	 Suppressed in overexpressing HE4 clones (16)
p38 p38 mitogen-activated protein kinase •	 Activated in NV cells treated with cisplatin and suppressed in  
overexpressing HE4 clones (16)
BCL2 B-cell lymphoma 2 •	 Increased in response to recombinant HE4 in vitro (7)
BAX bcl-2-like protein 4 •	 Decreased in response to recombinant HE4 in vitro (7)
MAPT Microtubule-associated protein tau •	 Upregulated in HE4-overexpressing clones (16)
SEPT3 Septin 3
TUBB β-Tubulin •	 Increased in response to recombinant HE4 in vitro (16)
ERK Extracellular signal-regulated kinase •	 Knockdown with HE4 lead to a reduction in cell growth and resensitization  
to cisplatin and paclitaxel (10)AKT Protein kinase B
(D) Steroid biosynthesis
FOXA2 Forkhead box protein A2 •	 Differentially expressed in -overexpressing clones and knockouts (71)
SQLE Squalene monooygenase •	 Differentially expressed in HE4-overexpressing clones and knockouts (71)
DHCR7 Dehydrocholesterol reductase
NSDHL Sterol-4-alpha-carboxylate-3 dehydrogenase
5-MC 5-Methylcytosine •	 Downregulated in HE4-overexpressing clones compared with wild-type  
SKOV3 cells and null vector (131)
ESR1 Estrogen/estrogen receptor •	 Abolished in HE4-overexpressing clones (131)
•	 When stimulated in H08910 cells HE4 increased in gene and protein levels.  
Effect not observed in SKOV3 cells (131)
•	 Increase expression in HE4 SKOV3 knockdown (131)
TABLe 1 | Continued
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and JUND) were differentially regulated in response to HE4 
overexpression in ES-2 cells (10).
Activation of the MAPK/ERK pathway occurs through EGF 
binding of its membrane bound receptor, EGFR (24). Using 
co-immunoprecipitation studies in SKOV3 cells, Moore et  al. 
found that HE4 interacts with EGFR, with a greater degree of 
immunoprecipitation seen in HE4-overexpressing clones than 
wild-type cells (15). Furthermore, ovarian xenograft tissue 
showed colocalization of HE4 and EGFR. In addition, when 
SKOV3 and OVCAR8 cells were stimulated with growth factors 
EGF, VEGF, and Insulin, nuclear localization of HE4 was signifi-
cantly increased. Finally, when EGF was repressed by the small 
molecule inhibitor Iressa, relative intensity of HE4 staining was 
decreased in ovarian cancer cell lines. Collectively, these results 
provide several layers of evidence that HE4 is tied to growth 
factor signaling and the MAPK/ERK pathway, although further 
research is needed to elucidate the precise mechanisms involved.
He4’s Role in Proliferation in Other 
Cancers
Human epididymis protein 4 has been investigated as a putative 
biomarker in endometrial (25–39), lung (40–52), breast (53, 54), 
pancreatic (55, 56), and gastric cancer (57). While the majority 
of these studies examine the value of HE4 as a clinical biomarker 
for detecting and monitoring disease, one study investigated the 
molecular mechanisms of HE4 in pancreatic and endometrial 
cancer. Lu et al. stimulated both pancreatic and endometrial can-
cer cell lines with recombinant HE4 and found that cell viability, 
cell growth, and DNA synthesis was increased prominently in 
both cancer types (56). They also report that HE4 upregulates 
gene expression of proliferating cell nuclear antigen (PCNA) and 
downregulates p21 in both cancer cell lines in a dose dependent 
manner. PCNA, which is expressed in the late G1/S phase of the 
cell cycle, is required for DNA repair, replication, cell prolifera-
tion, and cell cycle progression (58), while p21 is an important 
effector of tumor suppressor pathways by promoting cell cycle 
arrest. Specifically, p21 is able to facilitate p53-dependent G1 
growth arrest (59). Therefore, results from this study highlight 
HE4’s role in proliferation in both pancreatic and endometrial 
cancer and lend support to similar evidence from studies pub-
lished on EOC.
iNvASiON, MiGRATiON, AND ADHeSiON
Several studies have associated HE4 with metastatic properties, 
including invasion, migration, and adhesion of ovarian cancer 
cells. Lu et al. found that adhesion to a fibronectin substrate was 
twofold greater in SKOV3 cells overexpressing HE4 than in mock 
cells. In addition, a transwell migration assay demonstrated that 
the HE4-overexpressing clones had a 1.8-fold greater migration 
capacity than mock transfected cells. By contrast, immuno-
fluorescence analysis showed that HE4 knockout clones displayed 
inhibited cell-spreading ability in a statistically significant fashion 
compared with respective controls. Furthermore, cell invasion, 
proliferation, and migration were significantly decreased in 
these clones (14). In agreement with this study, Ribeiro et  al. 
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also found that OVCAR8 ovarian cells treated with recombinant 
HE4 exhibited 2.07-fold greater invasion capacity and 1.29-fold 
greater adhesion to a fibronectin matrix compared with untreated 
controls. Interestingly, there was no change in adhesion to colla-
gen I, IV, laminin I, and fibrinogen matrices, suggesting that HE4 
has a specific effect on fibronectin adhesion. Haptotaxis toward 
a fibronectin substrate also was increased in the ovarian cancer 
cells treated with recombinant HE4 by 1.72-fold (60).
Zhu et al. used wound healing and transwell invasion assays 
to show that HE4-overexpressing ES-2 and CaOV3 cells possess 
enhanced cell migration and invasion capacities. In addition, 
in vivo tail vein injection of HE4-overexpressing ES-2 cells into 
nude mice resulted in significantly more metastatic lung nodules 
than mock transfected cells (10). Using the same ovarian cancer 
cell lines, Zhuang et al. report the importance of HE4 interaction 
with annexin II (ANXA2) to promote invasion and migration 
in vitro and metastasis in vivo (61). Finally, Zou et al. found that 
knockdown of HE4 in SKOV3.ip1 cells inhibited migration and 
invasion (62). Taken together, these studies strongly suggest that 
HE4 plays a prominent role in the promotion of ovarian cancer 
metastasis. A full list of factors associated with HE4-mediated 
invasion, migration, and adhesion can be found in Table 1B and 
is outlined in greater detail below.
Associated Pathways and Factors—
invasion, Migration, and Adhesion
Human epididymis protein 4 appears to interact with numerous 
molecular pathways that promote metastasis in ovarian cancer. 
However, it is still not entirely known how HE4 affects signaling 
pathways and gene expression signatures to promote invasion, 
migration, and adhesion of ovarian cancer cells. Following is a 
summary of HE4-mediated molecular pathways that are involved 
in metastatic events in EOC.
Matrix Metalloproteinases (MMPs)
Human epididymis protein 4 has been associated with MMPs 
MMP-9 and MMP-2, and Cathepsin B. MMPs are a family of 
zinc-dependent endopeptidases that are vital for the remodeling 
of the extracellular matrix (63). They are expressed in almost all 
types of cancers and are responsible for stimulating angiogenesis, 
tumor growth, and metastasis (64, 65). Cathepsin B is a lysosomal 
cysteine protease that has been linked to cancer progression (66), 
specifically in signaling pathways related to angiogenesis (67). 
In addition, it can promote MMP activity by degrading MMP 
inhibitors (68). Interestingly, silencing of HE4 in ovarian cancer 
cells led to a decrease in protein levels of MMP-9, MMP-2, and 
Cathepsin B, suggesting these factors may be involved in HE4-
mediated tumor promoting effects (11).
Interleukin-1 Alpha (IL1A)
Interleukin-1 alpha is a pro-inflammatory cytokine that is 
involved in angiogenesis and metastasis. ILIA can directly 
stimulate the synthesis of VEGF (69) and fibroblastic pro matrix 
metallic proteinase I (70, 71). IL1A causes resistance to EGFR 
inhibitors in both colon and head and neck cancers (72, 73). IL1A 
was also found to be differentially expressed in three separate 
microarray studies involving HE4. In two microarrays, IL1A 
levels positively associated with HE4 levels (10, 74), while in one 
study their levels were inversely associated (18). While there may 
be some ambiguity as to how HE4 and IL1A are mechanistically 
linked, the consistent connection between IL1A with HE4 merits 
further investigation.
Extracellular Matrix Proteins
Integrins are a family of transmembrane proteins that are vital 
to ECM adhesion and play important roles in wound healing as 
well as the pathogenesis of cancer (75–77). Integrin β5 (ITGβ5) 
gene expression was differentially regulated by HE4 in ES-2 and 
CaOV3 cells, which was confirmed by positive correlation of 
ITGB5 and HE4 staining in paraffin embedded ovarian tissue 
samples (10). This finding suggests that integrin signaling is 
one mechanism by which HE4 can promote increased adhesion 
of ovarian cancer cells. However, further research is needed to 
clarify the mechanisms involved.
In addition to ITGβ5, three other genes related to ECM mod-
eling—syndecan 1 (SDC1), collagen type 1 alpha 1 (COL1A1), 
and dystroglycan 1 (DAG1)—were more highly expressed in cells 
overexpressing HE4 and were downregulated in cells with HE4 
knockdown (10). SDC1, also known as CD138, is an essential 
cell surface adhesion molecule that is responsible for maintaining 
cell morphology and interactions within the surrounding micro-
environment (78). Loss of SCD1 in cancer cells is associated with 
reduced ECM adhesion and enhanced invasion and cell motility 
(79). Another ECM gene found to be affected by HE4 expression 
levels, COL1A1, is a crucial component of the ECM as it supports 
cartilage, bone, and tendon tissues in the body and also functions 
to maintain the rigidity and elasticity of tissues (80, 81). COL1A1 
plays an important role in cancer, since tumor cells that express 
COL1A1 are able to dissociate from their surrounding stromal 
components, which is essential for tumor growth (81). The final 
ECM gene found to be affected by HE4 is DAG1, which is a cell 
adhesion molecule that plays a key role basement membrane 
assembly (82), muscle integrity (83), and the maintenance of 
basolateral cell adhesion in numerous epithelial tissues (84). 
Loss of DAG1 is associated with cancer progression (85). Taken 
together, these results show that HE4 is strongly interconnected 
with ECM related proteins, specifically those involved in the 
ITGβ5 signaling pathway.
Our lab has also determined that HE4 regulates several compo-
nents of the extracellular matrix (60). We performed microarray 
analyses comparing untreated OVCAR8 wild-type cells to recom-
binant HE4 treated cells, and OVCAR8 cells overexpressing HE4 
to null-vector control cells. Serpin peptidase inhibitor, member 
2 (SERPINB2), gremlin 1 (GREM1), laminin-β3 (LAMB3), 
laminin-γ2 (LAMC2), fibroblast growth factor 5 (FGF5), and 
tenascin C (TNC) were all found to be significantly upregulated 
upon treatment with recombinant HE4. These genes encode 
for extracellular matrix proteins that promote cell migration 
and adhesion (60). Specifically, we found that HE4 upregulates 
LAMC2 and LAMB3 proteins in a time-dependent manner, 
and this increase of both factors in turn leads to an increase in 
laminin-332 levels (60). Laminin-332, a heterotrimer composed 
of LAMC2, LAMB3, and LAMA2, is an important component of 
the basement membrane in epithelial tissue. Abnormal increases 
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in its levels have been shown to promote increased invasion in 
cancers (86). Further evidence suggested involvement of the FAK 
pathway in these events. In addition, activation of matriptase, a 
serine protease responsible for cleaving laminin-332 in its β chain 
and regulating its effects on metastatic properties, increased upon 
in vitro exposure to recombinant HE4 (60). This study provides 
compelling evidence that HE4 is involved in basement membrane 
invasion and adhesion.
Lewis y Antigen
Human epididymis protein 4 undergoes glycosylation before 
it is secreted by ovarian cells (87), prompting Zhuang et  al. to 
examine the relationship between HE4 glycosylation status and 
metastatic properties. Lewis y antigen is a glycosyl antigen that 
is overexpressed in ovarian cancer and has been associated with 
chemoresistance and poor prognosis (88–97). They determined 
that Lewis y antigen was present in HE4 from benign and malig-
nant ovarian tissues, in vitro cancer cells, and culture medium. 
HE4 from ovarian cancer samples contained higher levels of 
Lewis y antigen than HE4 from benign tissues, and their expres-
sion co-localized in ovarian cancer tissue (98). Furthermore, 
when Lewis y antigen was over expressed, it promoted HE4-
mediated invasion and metastasis in ovarian cancer cell lines. 
Conversely, when Lewis y antigen was blocked, the invasive and 
metastatic properties of HE4 were significantly decreased (99). 
Interestingly, overexpression of Lewis y antigen increased tyros-
ine phosphorylation of EGFR and HER/neu, which promoted 
cell proliferation through the PI3K/Akt and Raf/MEK/MAPK 
pathways (100). Thus, it appears that Lewis y antigen and HE4 
affect similar signaling pathways that promote tumor growth and 
malignancy (101). Taken together, these results show that Lewis 
y antigen could be a potential therapeutic target to decrease HE4 
function in the treatment of EOC.
Heparin Cofactor II (HCII)
SERPIND1 encodes for the protein HCII, which is a serum 
glycoprotein and protease inhibitor (102). A study in non-small 
cell lung cancer (NSCLC) showed that HCII promotes cell motil-
ity, invasion, and filopodium dynamics through the PI3K/AKT 
pathway. High HCII expression in NSCLC tissue correlated to 
an increased recurrence rate and shorter overall survival (103). 
Furthermore, its levels were upregulated in metastatic brain cell 
lines compared with non-metastatic parental lines, suggesting an 
involvement of SERPIND1 in metastatic functions (104). Results 
from a microarray study by Zhu et al. showed that SERPIND1 
was upregulated in HE4-overexpressing cells and conversely 
downregulated in HE4 knockdown cells. These results were 
validated via qPCR and immunohistochemistry. In addition, 
they found that 37/50 ovarian cancer samples showed positive 
expression of both SERPIND1 and HE4, and Spearman correla-
tion analysis confirmed that HE4 and SERPIND1 were positively 
correlated. Finally, Kaplan–Meier analysis revealed that patients 
with high levels of HE4 and SERPIND1 had a worse prognosis 
(74). While these data strongly suggest a connection between 
HE4 and SERPIND1, which may be related to their roles in pro-
moting ovarian cancer metastasis, further study of the association 
between these two proteins is required.
Annexin II
Annexin II is a calcium-dependent, phospholipid-binding pro-
tein that is overexpressed in a variety of cancers and is involved 
in angiogenesis, proliferation, apoptosis, cell migration, invasion, 
and adhesion (105). High levels of Annexin II activate MAPK 
signaling, which in turn promotes tumor proliferation (106), 
invasion (107), and metastasis (108). Zhuang et al. employed mass 
spectrometry and co-immunoprecipitation to identify Annexin II 
(ANXA2) as a strong HE4 interacting partner (61). This binding 
promoted invasion and metastasis in ES-2 and CaOV3 ovarian 
cancer cells. HE4 and ANXA2 gene expression levels were found 
to be co-dependent, and examination of EOC tissue revealed that 
both HE4 and Annexin II levels were increased in malignant phe-
notypes compared with benign and normal ovarian tissues. Both 
proteins were also more highly expressed in tissues from patients 
with lymph node metastases than those without. Downregulation 
of HE4 was found to decrease expression of MKNK2 (MAP 
kinase-interacting serine/threonine-protein kinase 2) and 
LAMB2 (laminin, beta-2), two factors associated with MAPK 
and focal adhesion signaling pathways. When HE4 protein was 
supplemented, this effect was reversed. Collectively, these results 
show that HE4 interaction with Annexin II to activate MAPK and 
focal adhesion signaling is one mechanism by which HE4 may 
promote ovarian cancer metastasis.
CHeMOReSiSTANCe
Several studies show that HE4 is associated with chemoresistance 
clinically. The addition of HE4 serum levels in the ROMA score 
better predicts platinum resistance in patients than CA125 alone 
(15). Angioli et al. found that HE4 was able to predict chemo-
therapy response in EOC patients undergoing first-line therapy 
(109). In addition, higher levels of serum HE4 are reported in 
women who are resistant to first-line chemotherapy (110). Finally, 
higher HE4 levels inversely correlate with clinical outcome (111), 
optimal cytoreduction (112), progression free survival (113), and 
overall survival (15, 113). While the mechanism underlying HE4’s 
contribution to chemoresistance has not been established fully, a 
few studies have begun to delineate HE4’s role in this process. A 
full list of factors associated with HE4-mediated chemoresistance 
can be found in Table 1C and is outlined in detail below.
Associated Pathways and Factors—
Chemoresistance
Antiapoptotic Gene Expression
A study performed in our lab by Ribeiro et al. determined that 
HE4 overexpression promotes collateral chemoresistance to 
both cisplatin and paclitaxel in SKOV3 and OVCAR8 cells 
(18). Conversely, CRISPR/Cas9 mediated knockdown of HE4 
in SKOV3 cells overexpressing HE4 partially reversed their 
chemoresistance. Microarray analysis revealed suppression of 
cisplatin-induced early growth response 1 (EGR1) gene expres-
sion in HE4-overexpressing SKOV3 cells compared with null 
vector-transfected cells (18). EGR1 is a transcription factor that 
regulates apoptosis, proliferation, and differentiation through 
regulating expression of genes such as p53, BCL2, PTEN, IGF2, 
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PDGF, VEGF, TGFB1, and TNF (114, 115). EGR1 expression 
is influenced by MAPK signaling, including phospho-ERK and 
phospho-p38 (115). Ribeiro et  al. found that p38 was strongly 
activated in SKOV3 null vector-transfected cells treated with cis-
platin, while its activation was suppressed in HE4-overexpressing 
clones (18), suggesting that HE4-mediated chemoresistance may 
involve MAPK signaling.
Similarly, a study by Wang et al. showed that HE4 represses 
carboplatin-induced apoptosis in vitro. Recombinant HE4 caused 
an increase in expression of antiapoptotic protein B-cell lym-
phoma 2 (BCL-2) and a decrease in expression of pro-apoptotic 
Bax (Bcl-2 associated X protein) in SKOV3 cells treated with 
carboplatin (9). This decrease in the Bax/Bcl-2 ratio, in addition 
to the suppression of EGR1 when HE4 is overexpressed, may 
contribute to the overall decrease in pro-apoptotic factors that 
leads to chemoresistance in EOC.
Microtubule Stabilization
Microtubule-associated protein tau, which has been associated 
with paclitaxel resistance in ovarian (116), breast (117), and 
gastric cancer (118), was upregulated in SKOV3 cells overex-
pressing HE4 compared with null-vector cells (18). In addition, 
HE4-overexpressing cells were found to express significantly 
higher levels of SEPT3 (Septin 3) mRNA compared with null-
vector controls (18). Septins are a family of conserved GTP 
binding proteins that are associated with microtubules and actin 
filaments and have an important role in cytoskeletal organization 
(119). Furthermore, recombinant HE4 treatment of SKOV3 cells 
increased β-tubulin levels, indicating that HE4 might promote 
microtubule stability, leading to paclitaxel resistance.
Kinase Signaling Pathways
Human epididymis protein 4 knockdown has also been shown 
to lead to a reduction in cell growth and the resensitization of 
ovarian cancer cells to both cisplatin and paclitaxel (12). Lee 
et al. found that this effect was due to corresponding decreases of 
ERK and AKT in HE4 knockouts. Activation of these pathways 
suppresses apoptotic signaling in tumors, suggesting that HE4’s 
regulation of these pathways may be an important mechanism of 
chemoresistance (120).
STeROiD BiOSYNTHeSiS
Evidence suggests an association between sex steroids and EOC 
pathogenesis, which is explained by processes that take place 
during the menstrual cycle. The ovarian surface epithelium 
(OSE) plays a critical role in ovulation and postovulatory wound 
repair. During the menstrual cycle, the OSE proliferates during 
the pro-estrus/estrus transition. After, ovulation the prolifera-
tion rate decreases (121). It is hypothesized that when the OSE 
is repeatedly exposed to high doses of luteinizing hormone and 
follicle stimulating hormone during the menstrual cycle, this can 
promote cell proliferation and increase the likelihood of tumor 
growth over time (121). Furthermore, epidemiological data 
have suggested that ovarian cancer progression, pathogenesis, 
and etiology are highly dependent on the activity of estrogens 
(121), and numerous experimental studies have demonstrated 
the promotive effect of estrogens on ovarian tumors in mice and 
human EOC cell lines (122). However, activation of diverse onco-
genic pathways in EOC may lead to the eventual downregulation 
of ERα levels and the overall decrease in ERα related signaling 
in ovarian cancers, rendering them resistant to anti-estrogen 
therapies (122). Some evidence exists that HE4 may be involved 
in this process by regulating steroid signaling in EOC. A full list 
of factors associated with HE4-mediated steroid biosynthesis can 
be found in Table 1D and is outlined in detail below.
Steroid Biosynthesis Gene expression
Two separate microarray pathway analyses identified steroid bio-
synthesis as a pathway affected by HE4 (10, 74). Important genes 
that were differentially expressed between HE4-overexpressing 
and HE4 knockdown cell lines were Forkhead box protein A2 
(FOXA2) (74), squalene monooygenase (SQLE), 7-dehydrocho-
lesterol reductase (DHCR7), 24-dehydrocholesterol (DHCR24), 
and sterol-4-alpha-carboxylate-3-dehydrogenase (NSDHL) (10). 
FOXA2, a transcription factor required for normal metabolism 
(123), promotes cell proliferation, maintains cancer stem cells, 
and is associated with a higher rate of relapse in triple-negative 
breast cancer (124).
Another gene differentially regulated by HE4, SQLE, is 
an enzyme required in the later stages of cholesterol synthesis 
(125). Out of 22 cancer types, SQLE copy number-driven gene 
expression was highest in breast, ovarian and colorectal cancer 
(125). Also affected by HE4 levels was DHCR7, one of the ter-
minal enzymes involved in the production of cholesterol from 
7-dehydrocholesterol (7DHC). DHCR7 was found to be an 
important regulatory determinate between cholesterol and vita-
min synthesis, as cholesterol is able to accelerate the proteasomal 
degradation of DHCR7, which can result in the accumulation of 
7DHC and an increased production of vitamin D (126). DHCR24, 
which was also affected by modulation of HE4 levels, is another 
enzyme in the cholesterol biosynthesis pathway (127). It interacts 
physically and functionally with DHCR7 (128) and has a number 
of different cellular functions including anti-inflammatory and 
antiapoptotic functions, as well as regulation of oxidative stress 
and cell differentiation (129). DHCR24 has also been proposed 
to be involved in tumor progression, as its deregulation has been 
linked to prostate, ovarian, and urothelial carcinomas (127).
Finally, NSDHL is also involved in cholesterol biosynthesis 
and produces metabolites that are essential in the conversion of 
squalene to cholesterol (130). Interestingly, NSLD1 was found 
to have a role in the control of signaling, vesicular trafficking, 
and degradation of EGFR and its dimerization partners ERBB2 
and ERBB3. A study by Sukhanova et  al. showed that NSLD1 
knockout in vivo leads to a reduction in EGFR activation (131). 
The results from these microarrays show that modulating HE4 
levels results in differential expression of several genes involved 
in steroid biosynthesis—especially cholesterol—suggesting that 
HE4 may affect tumor metabolism and ultimately contribute to 
tumorigenesis.
estrogen Signaling
In support of the above described pathway analyses, two other 
studies have shown that HE4 interacts with steroid signaling, 
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specifically estrogen signaling. Lokich et  al. showed that ERα 
expression was reduced in HE4-overexpressing SKOV3 cells, 
resulting in increased resistance to tamoxifen and fulvestrant 
compared with wild-type cells (132). 5-Methylcytosine (5-MC), 
a methylated form of the DNA base cytosine, is one of the most 
prominently identified epigenetic modifications, and can cause 
suppression of ERα gene expression. Deregulation of DNA 
methylation can result in abnormal gene expression and tumo-
rigenesis (133, 134). Lokich et al. found that 5-MC was readily 
detected in SKOV3 wild-type and null-vector cells but not in 
HE4-overexpressing clones, suggesting that HE4 overexpression 
may have an effect on epigenetic modifications (132). However, 
methylation of the ERα gene was not specifically examined in this 
study. It is unclear whether HE4 overexpression would promote 
increased methylation at the ERα promoter region (even with 
the presence of global demethylation), which would be expected 
given the reported suppression of ERα in this study.
Interestingly, Chen et al. reported that when HO8910 ovarian 
cancer cells were stimulated with estradiol (E2), there was an 
increase in the expression of HE4 at the mRNA and protein level. 
This effect was not observed in estrogen-insensitive SKOV3 cells; 
however, when HE4 was knocked down in SKOV3 cells, their 
proliferative response to estrogen was restored (135). Collectively 
with the results shown by Lokich et al, this study suggests that 
HE4 works to suppress estrogen signaling in ovarian cancer cells, 
which can contribute to resistance to anti-estrogen therapies. 
Conversely, it appears that estradiol promotes HE4 expression in 
estrogen-responsive cells, which could indicate a role for HE4 in 
the initial tumor promoting effects of estrogen. Further clarifica-
tion of the effect of HE4 on estrogen signaling may be useful in 
improving implementation of anti-estrogen based therapies.
CONCLUSiON
Ovarian cancer is an extremely deadly disease owing to the fact 
that patients are typically diagnosed at a late stage. Initially, 
patients respond well to frontline platinum therapy; however, a 
majority of tumors recur, and the initial chemosensitivity eventu-
ally gives way to a broad chemoresistance (136). Available detec-
tion methods have improved in recent years with the discovery 
of HE4 as a diagnostic and prognostic biomarker. However, there 
has yet to be a breakthrough targeted therapy to combat EOC. 
While PARP inhibitors are used in the maintenance setting for 
all patients, this therapy has most significantly benefited BRCA-
positive patients, who comprise only 20–25% of patients (137, 
138). In addition, inhibitors of immune checkpoints, such as 
programmed death ligand-1 have demonstrated modest benefit 
in clinical trials for ovarian cancer (139). Therefore, there is still 
a crucial need for novel targeted EOC treatments.
Although HE4 is well established as a clinical biomarker 
for ovarian cancer, it has been largely understudied for its 
therapeutic targeting potential. However, ongoing research 
continues to support that HE4 is profoundly involved in the 
pathogenesis of EOC. The individual studies mentioned in this 
review provide evidence that HE4 promotes EOC progression 
through pathways associated with cell proliferation, tumor 
growth, metastasis, chemoresistance, and steroid biosynthesis. 
These pathways, along with specific genes that have been shown 
to be associated with HE4, are summarized in Table  1. This 
compilation of HE4 regulated factors and pathways will serve 
as a starting point for scientists to further elucidate specific 
mechanisms by which HE4 ultimately drives tumorigenesis. 
In addition, a comprehensive summary of clinical, in vivo, and 
in vitro studies related to each facet of EOC progression and HE4 
can be seen in Figure 1. This diagram highlights the progress 
that has been made to establish HE4 as an attractive therapeutic 
target, while simultaneously denoting areas of research that are 
still lacking. The results discussed here suggest that inhibition 
of HE4 via a neutralizing antibody or small molecule inhibitor 
could provide viable treatment options for patients in dire need 
of more effective therapies.
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